Cello Health PLC Issue of Equity (6052Z)
May 20 2019 - 10:29AM
UK Regulatory
TIDMCLL
RNS Number : 6052Z
Cello Health PLC
20 May 2019
20 May 2019
Cello Health plc
("Cello" or the "Company")
Issue of Equity
Further to the announcement released on 1 February 2017
regarding the acquisition of the assets of Defined Healthcare
Research, Inc, and Cancer Progress, LLC ("Defined Health") by the
Company, Cello today announces that the first deferred
consideration payments to the vendors of Defined Health have now
been settled.
To part satisfy the deferred consideration, the Company has
applied for the admission of 320,243 new ordinary shares of 10
pence each in the Company ("Ordinary Shares") to trading on AIM,
which is expected to occur on 24 May 2019.
Following admission, Cello's issued share capital will consist
of 105,545,545 Ordinary Shares, of which 453,000 Ordinary Shares
are held in treasury. The total number of current voting rights in
the Company will therefore be 105,092,545 Ordinary Shares.
The above figure (105,092,545 Ordinary Shares) may be used by
shareholders as the denominator for the calculation by which they
will determine if they are required to notify their interest in, or
a change in their interest in, the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Enquiries:
Cello Health plc 020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Group Finance Director
Cenkos Securities plc 020 7397 8900
Mark Connelly
Harry Hargreaves
Buchanan
Mark Court 020 7466 5000
Jamie Hooper
Sophie Wills
About Cello Health plc
We are a global healthcare-focused advisory Group comprised of a
set of leading clinical, commercial advisory and digital delivery
capabilities. We currently service 24 of the top 25 pharmaceutical
clients globally as well as a wide range of biotech, diagnostics,
devices and other key non-healthcare clients.
We enable clients to differentiate their propositions and drive
brand success in ever more complex global markets. We deliver our
services through nearly 1,000 highly skilled professionals
utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in
the UK, USA, Germany and Asia, with hub offices in New York,
Philadelphia, London, Berlin, Edinburgh, Farnham and
Cheltenham.
For further information, please visit:
https://cellohealthplc.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEURUVRKNAVUAR
(END) Dow Jones Newswires
May 20, 2019 11:29 ET (15:29 GMT)
Cello Health (LSE:CLL)
Historical Stock Chart
From Apr 2024 to May 2024
Cello Health (LSE:CLL)
Historical Stock Chart
From May 2023 to May 2024